Last edition
News about Global Pharma
Boston Scientific will acquire Penumbra in a USD 14.5 billion cash and stock deal to expand its vascular and neurovascular portfolio, strengthening its position in thrombectomy, stroke, and cardiovascular disease treatment markets.
Global Pharma | 17/01/2026 | By News Bureau | 226
Miach Orthopaedics’ BEAR Implant becomes the first sports medicine device to carry an FDA-cleared claim for lowering long-term osteoarthritis risk compared with traditional ACL reconstruction.
Global Pharma | 16/01/2026 | By News Bureau | 405
The silicon photonics based imaging platform, Leadoptik’s LIA system, delivers real-time, high-resolution tissue insight at the point of care, addressing a critical gap in lung cancer diagnosis.
Global Pharma | 16/01/2026 | By News Bureau | 344
Novo Nordisk Foundation Awards DKK 5.5 Billion to Boost Innovation in Denmark and Europe
The Novo Nordisk Foundation has awarded DKK 5.5 billion to support innovation in Denmark and Europe, enabling BioInnovation Institute (BII) to expand into new strategic areas and geographies. The funding aims to back a larger number of entrepreneurs and start-ups, strengthening the region’s life sciences and innovation ecosystem.
Global Pharma | 16/01/2026 | By News Bureau | 120
Sanofi Warns of Near-Term Weakness in US Vaccine Demand Amid Antivax Rhetoric
French pharmaceutical company Sanofi expects near-term weakness in vaccine sales in the United States, attributing the anticipated softness to growing scepticism around immunizations that the company says has been fueled by misinformation.
Global Pharma | 15/01/2026 | By Darshana | 212
Bayer Targets Return to Mid-Single-Digit Pharma Growth by 2027
Addressing investors at a major healthcare conference, Stefan Oelrich, head of Bayer’s pharmaceuticals business, said the company expects 2026 to be the final year significantly affected by the loss of exclusivity on its blockbuster anticoagulant Xarelto. From 2027 onward, Bayer anticipates a recovery driven by newer medicines and pipeline progress.
Global Pharma | 14/01/2026 | By Darshana | 570
Enspire DBS Therapy Raises USD 10.3M Series B1 to Advance Post-Stroke Neuromodulation Trial
The funding led by Genesys Capital will support continued enrollment in Enspire’s pivotal restore clinical trial evaluating deep brain stimulation combined with rehabilitation for stroke recovery.
Global Pharma | 14/01/2026 | By News Bureau | 275
Novartis, SciNeuro Sign USD 1.7 Billion Licensing Deal to Develop Alzheimer's Therapies
Novartis has entered into an exclusive global licensing and collaboration agreement with SciNeuro Pharmaceuticals to develop and commercialize novel therapies for Alzheimer’s disease, in a deal valued at up to USD 1.7 billion.
Global Pharma | 13/01/2026 | By Darshana | 342
Just-Evotec Biologics Secures Gates Foundation Grant to Expand Global Access to Biotherapeutics
The funding will support ten new molecular design projects over three years, leveraging Just-Evotec Biologics’ J.MD computational platform to optimise monoclonal antibodies and other biologics, reduce development costs and improve access to affordable therapies for infectious diseases in low- and middle-income countries.
Global Pharma | 12/01/2026 | By News Bureau | 140
Shilpa Medicare Targets US Approval for Oeris After Successful Phase Three Trial
Shilpa Medicare seeks licensing partners for extended-release ondansetron injection to treat chemotherapy-induced nausea and vomiting.
Global Pharma | 09/01/2026 | By News Bureau | 169
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy